Sarepta Announces Positive Safety and Efficacy Data from SRP-9001 Gene Therapy Trial Published
Sarepta Therapeutics today announced safety and tolerability data at one year from four Duchenne clinical trial participants who received SRP-9001 micro-dystrophin (AAVrh74.MHCK7.micro-dystrophin) have been published in JAMA Neurology. PPMD is proud to have been an…Learn More